Compare Cigna Corp (CI) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $61.7 (market cap $79.91B). The key difference: Cigna Corp and MONDELEZ INTERNATIONAL INC Common Stock are close in size by market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| CI | MDLZ | |
|---|---|---|
Market Cap | $73.56B | $79.91B |
Sector | Health | Consumer Staples |
52-Week High | $311.00 | $64.99 |
52-Week Low | $244.41 | $51.51 |
Enterprise Value | $98.27B | $100.25B |
Dividend Yield | 2.24% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
MDLZ trades at $62.61, down 0.22% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. Recent Q2 2026 earnings beat estimates with EPS of $0.73 versus $0.68 expected, driven by 2.2% organic revenue growth. The company raised its 2026 organic sales outlook, supported by strength in emerging markets and improved execution in North America. Cash flow from operations remains robust at $4.5 billion in 2025, though net income margin dipped to 6.36% from higher costs.
Outlook is positive with a consensus price target of $70.50, implying 12.6% upside, and 76% of analysts rate it a buy. Risks include reliance on international sales exposure to currency fluctuations and competitive pressures in the snack industry. Valuation multiples like P/E of 38.25 appear elevated relative to historical norms, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
